GENFIT announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market




GENFIT announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market

Lille (France), Cambridge (Massachusetts, United States), (Zurich, Switzerland); November 20, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces that the Company’s voluntary delisting of American Depositary Shares (“ADSs”) representing its ordinary shares from The Nasdaq Global Select Market (“Nasdaq”) has become effective. Each ADS represents one ordinary share of the Company. The Company has also filed a Form 15F with the Securities and Exchange Commission (“SEC”) to suspend its reporting obligations under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), in respect of the ADSs and the ordinary shares. The Company expects that the deregistration of the ADSs under the Exchange Act will become effective 90 days after the filing of the Form 15F.

Information for ADS Holders

The Bank of New York Mellon serves as depositary (the “Depositary”) for the Company’s ADS facility. Each ADS represents one ordinary share. GENFIT intends to terminate the Deposit Agreement, dated March 26, 2019, among the Company, the Depositary and owners and holders of ADSs (the “Deposit Agreement”) on or about February 6, 2026. As a result, the existing facility will be terminated effective at 5:00 PM (Eastern Time) on February 5, 2026.

Under the terms of the Deposit Agreement, ADS holders will have until February 9, 2026 to surrender ADSs for delivery of the underlying ordinary shares. If they surrender ADSs for delivery of the underlying ordinary shares, they must pay a cancellation fee of up to $0.05 per ADS and a cable fee of $17.50. In order to exchange ADSs for the Company’s ordinary shares, ADS holders should instruct their brokers to surrender ADSs to The Bank of New York Mellon (DTC No. 2504). In connection with this surrender, brokers should include ongoing ordinary share delivery instructions in the comments field within DTC, including information such as the name and BIC of the appropriate local bank/broker and/or appropriate delivery code, beneficiary name and account number. U.S. brokers holding ADSs on behalf of their clients, can reach out to DRSettlements@BNYMellon.com for questions regarding the conversion and settlement process.

Subsequent to February 9, 2026, the Depositary may elect to sell the underlying ordinary shares. If the Depositary has sold such shares, holders of ADSs must surrender such securities in order to obtain payment of the sale proceeds of the underlying ordinary shares, net of the expenses of sale, any applicable U.S. or local taxes or government charges and a cancellation fee of up to $0.05 per ADS.

To surrender American Depositary Receipts (“ADRs”), the address of the Depositary is: The Bank of New York Mellon, 240 Greenwich Street, New York, New York 10286, Attention: Depositary Receipt Administration. Registered or overnight mail is the suggested method of delivering ADRs to the Depositary. For Settlement specific inquiries, please contact DRSettlements@BNYMellon.com.

Investors may still present ADSs to The Bank of New York Mellon. Investors will receive either the underlying ordinary shares (if those have not yet been sold by the Depositary) or the cash received by the Depositary received upon sale of underlying ordinary shares, net of fees, if those underlying ordinary shares were sold. For more information, investors should contact DRSettlements@BNYMellon.com.

ABOUT GENFIT

GENFIT is a biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades.

Today, GENFIT focuses on Acute on-chronic Liver Failure (ACLF) and associated conditions such as acute decompensation (AD) and hepatic encephalopathy (HE). It develops therapeutic assets which have complementary mechanisms of action, selected to address key pathophysiological pathways. GENFIT also targets other serious diseases, such as cholangiocarcinoma (CCA), urea cycle disorders (UCD) and organic acidemia (OA). Its R&D portfolio, covering several stages of development, ensures a constant news flow.

GENFIT’s expertise in developing high-potential molecules – from early to advanced pre-commercialization stages – culminated in 2024 with the accelerated approval of Iqirvo^® (elafibranor) by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom for the treatment of Primary Biliary Cholangitis (PBC). Iqirvo^® is now marketed in several countries.¹  

Beyond therapies, GENFIT also has a diagnostic franchise including NIS2+^® for the detection of Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH for non-alcoholic steatohepatitis).

GENFIT is headquartered in Lille, France and has offices in Paris (France), Zurich (Switzerland) and Cambridge, MA (USA). The Company is listed on the Nasdaq Global Select Market and on the Euronext regulated market in Paris, Compartment B (Nasdaq and Euronext: GNFT). In 2021, Ipsen became one of GENFIT’s largest shareholders, acquiring an 8% stake in the Company’s capital. www.genfit.com

FORWARD LOOKING STATEMENTS

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to GENFIT, including, but not limited to statements about the Company’s expectation that the deregistration of the ADSs under the Exchange Act will become effective 90 days after the filing of the Form 15F. The use of certain words, such as “believe”, “potential”, “expect”, “target”, “may”, “will”, “should”, “could”, “if” and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company’s management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among others, the uncertainties inherent in research and development, including in relation to non-clinical and pre-clinical programs, reproducibility of preclinical results, the translation of animal model data to human biology, in relation to non-clinical and pre-clinical programs, reproducibility of preclinical results, the translation of animal model data to human biology, in relation to safety of drug candidates, cost of, progression of, and results from, our ongoing and planned clinical trials, patient recruitment, review and approvals by regulatory authorities in the United States, Europe and worldwide, of our drug and diagnostic candidates, pricing, approval and commercial success of elafibranor in the relevant jurisdictions, exchange rate fluctuations, and our continued ability to raise capital to fund our development, as well as those risks and uncertainties discussed or identified in the Company’s public filings with the AMF, including those listed in Chapter 2 “Risk Factors and Internal Control” of the Company’s 2024 Universal Registration Document filed on April 29, 2025 (no. 25-0331) with the Autorité des marchés financiers (“AMF”), which is available on GENFIT’s website (www.genfit.fr) and the AMF’s website (www.amf.org), and those discussed in the public documents and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s 2024 Annual Report on Form 20-F filed with the SEC on April 29, 2025 and subsequent filings and reports filed with the AMF or SEC, including the Half-Year Business and Financial Report at June 30, 2025 or otherwise made public, by the Company. In addition, even if the results, performance, financial position and liquidity of the Company and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this press release. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise.

CONTACT

GENFIT | Investors
Tel : + 33 3 20 16 40 00 | investors@genfit.com

GENFIT | Press relations

Stephanie BOYER | Tel : + 33 3 20 16 40 00 | stephanie.boyer@genfit.com

1 Elafibranor is marketed and commercialized, notably in the U.S and Europe, by Ipsen under the trademark Iqirvo^®

Attachment

• GENFIT announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market

MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors




MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors

• MiNK-215, an IL-15 armoured FAP-targeting CAR-iNKT, targets and clears tumor-protective FAP+ fibroblasts to allow immune cells to infiltrate and kills cancer cells
• Activates multiple immune pathways to generate potent, lasting anti-tumor activity in lung and MSS colorectal cancer models

NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced the publication of new preclinical data for MiNK-215, a novel, next-generation FAP-targeting, IL-15–enhanced CAR-iNKT therapy. The manuscript, titled The allogeneic FAP-CAR-IL15 iNKT therapy MiNK-215 remodels the tumor stroma to enhance antitumor immunity”, is now available on Cancer Immunology Research website here.

MiNK-215 is engineered to eliminate FAP-positive cancer-associated fibroblasts (CAFs)—the cells that build the dense, immunosuppressive stroma blocking immune infiltration in solid tumors and contributing heavily to immunotherapy failure. Using MiNK’s proprietary allogeneic platform, MiNK-215 also secretes IL-15 to enhance persistence, immune activation, and durability.

Key Findings: MiNK-215 tackles the two fundamental barriers: the physical stroma that blocks immune entry and the dysfunctional immune circuitry inside the tumor. Specifically,

• Dismantles the protective stromal barrier and selectively eliminates FAP+ cancer-associated fibroblasts, clearing the path for robust immune infiltration.
• Reprograms the immune landscape in preclinical models of refractory lung and MSS colon cancer liver metastases, MiNK-215:
  • Remodeled the tumor microenvironment
  • Activated dendritic cells and antigen-presentation pathways
  • Re-polarized macrophages to pro-inflammatory, cancer killing state
  • Enabled deep infiltration of tumor-specific T cells

As an “off-the-shelf” therapy, MiNK-215 can be manufactured at scale and delivered on demand—offering a new therapeutic strategy for patients with solid tumors that have long been unresponsive to checkpoint inhibitors and other immune-based treatments.

“The findings published today underscore the real potential of MiNK-215 to reshape how we treat solid tumors that have resisted immunotherapy for decades. By dismantling the fibroblast barriers that shield these cancers and activating multiple arms of the immune system, MiNK-215 goes beyond traditional checkpoint approaches. As an allogeneic, off-the-shelf therapy, it represents a meaningful step toward delivering scalable, immediate immune engagement for patients who currently have few effective options,” said Jennifer Buell, PhD, President and CEO of MiNK Therapeutics.

About MiNK Therapeutics

MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the development of allogeneic invariant natural killer T (iNKT) cell therapies and precision immune modulators designed to restore immune balance and drive durable cytotoxic responses. MiNK’s proprietary iNKT platform bridges innate and adaptive immunity to address cancer, autoimmune disease, and immune collapse.

Its lead candidate, AgenT-797, is an off-the-shelf, cryopreserved iNKT cell therapy currently in clinical trials for solid tumors, graft-versus-host disease (GvHD), and critical pulmonary immune failure. MiNK’s pipeline also includes TCR-based and neoantigen-targeted iNKT programs that enable tissue-specific immune activation. With a scalable manufacturing process and broad therapeutic potential, MiNK is advancing a new class of immune reconstitution therapies designed to deliver durable, accessible, and globally deployable treatments.

About MiNK-215
MiNK-215 is engineered to eliminate FAP-positive cancer-associated fibroblasts (CAFs)—the cells that build the dense, immunosuppressive stroma blocking immune infiltration in solid tumors and contributing heavily to immunotherapy failure. Using MiNK’s proprietary allogeneic platform, MiNK-215 also secretes IL-15 to enhance persistence, immune activation, and durability.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding the potential, safety, clinical benefit, and development plans for AgenT-797 and other iNKT-based therapies. These statements involve risks and uncertainties, including those described under “Risk Factors” in MiNK’s most recent SEC filings. MiNK undertakes no obligation to update these statements except as required by law.

Contacts

Investor Contact: 917-362-1370 | investor@minktherapeutics.com
Media Contact: 781-674-4428 | communications@minktherapeutics.com
Source: MiNK Therapeutics

MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors




MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors

• MiNK-215, an IL-15 armoured FAP-targeting CAR-iNKT, targets and clears tumor-protective FAP+ fibroblasts to allow immune cells to infiltrate and kills cancer cells
• Activates multiple immune pathways to generate potent, lasting anti-tumor activity in lung and MSS colorectal cancer models

NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced the publication of new preclinical data for MiNK-215, a novel, next-generation FAP-targeting, IL-15–enhanced CAR-iNKT therapy. The manuscript, titled The allogeneic FAP-CAR-IL15 iNKT therapy MiNK-215 remodels the tumor stroma to enhance antitumor immunity”, is now available on Cancer Immunology Research website here.

MiNK-215 is engineered to eliminate FAP-positive cancer-associated fibroblasts (CAFs)—the cells that build the dense, immunosuppressive stroma blocking immune infiltration in solid tumors and contributing heavily to immunotherapy failure. Using MiNK’s proprietary allogeneic platform, MiNK-215 also secretes IL-15 to enhance persistence, immune activation, and durability.

Key Findings: MiNK-215 tackles the two fundamental barriers: the physical stroma that blocks immune entry and the dysfunctional immune circuitry inside the tumor. Specifically,

• Dismantles the protective stromal barrier and selectively eliminates FAP+ cancer-associated fibroblasts, clearing the path for robust immune infiltration.
• Reprograms the immune landscape in preclinical models of refractory lung and MSS colon cancer liver metastases, MiNK-215:
  • Remodeled the tumor microenvironment
  • Activated dendritic cells and antigen-presentation pathways
  • Re-polarized macrophages to pro-inflammatory, cancer killing state
  • Enabled deep infiltration of tumor-specific T cells

As an “off-the-shelf” therapy, MiNK-215 can be manufactured at scale and delivered on demand—offering a new therapeutic strategy for patients with solid tumors that have long been unresponsive to checkpoint inhibitors and other immune-based treatments.

“The findings published today underscore the real potential of MiNK-215 to reshape how we treat solid tumors that have resisted immunotherapy for decades. By dismantling the fibroblast barriers that shield these cancers and activating multiple arms of the immune system, MiNK-215 goes beyond traditional checkpoint approaches. As an allogeneic, off-the-shelf therapy, it represents a meaningful step toward delivering scalable, immediate immune engagement for patients who currently have few effective options,” said Jennifer Buell, PhD, President and CEO of MiNK Therapeutics.

About MiNK Therapeutics

MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the development of allogeneic invariant natural killer T (iNKT) cell therapies and precision immune modulators designed to restore immune balance and drive durable cytotoxic responses. MiNK’s proprietary iNKT platform bridges innate and adaptive immunity to address cancer, autoimmune disease, and immune collapse.

Its lead candidate, AgenT-797, is an off-the-shelf, cryopreserved iNKT cell therapy currently in clinical trials for solid tumors, graft-versus-host disease (GvHD), and critical pulmonary immune failure. MiNK’s pipeline also includes TCR-based and neoantigen-targeted iNKT programs that enable tissue-specific immune activation. With a scalable manufacturing process and broad therapeutic potential, MiNK is advancing a new class of immune reconstitution therapies designed to deliver durable, accessible, and globally deployable treatments.

About MiNK-215
MiNK-215 is engineered to eliminate FAP-positive cancer-associated fibroblasts (CAFs)—the cells that build the dense, immunosuppressive stroma blocking immune infiltration in solid tumors and contributing heavily to immunotherapy failure. Using MiNK’s proprietary allogeneic platform, MiNK-215 also secretes IL-15 to enhance persistence, immune activation, and durability.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding the potential, safety, clinical benefit, and development plans for AgenT-797 and other iNKT-based therapies. These statements involve risks and uncertainties, including those described under “Risk Factors” in MiNK’s most recent SEC filings. MiNK undertakes no obligation to update these statements except as required by law.

Contacts

Investor Contact: 917-362-1370 | investor@minktherapeutics.com
Media Contact: 781-674-4428 | communications@minktherapeutics.com
Source: MiNK Therapeutics

Channel Medsystems Appoints Robert Brown, MBA, CPA, as Chief Financial Officer




Channel Medsystems Appoints Robert Brown, MBA, CPA, as Chief Financial Officer

BERKELEY, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) — Channel Medsystems, Inc., a privately held company dedicated to advancing women’s health with innovative solutions, announced today the appointment of Robert Brown, MBA, CPA, as Chief Financial Officer.

Mr. Brown is a seasoned financial executive with deep expertise in strategic finance, operations, and growth planning for healthcare and medtech organizations. As an MBA and CPA, he brings the combination of strong financial acumen, regulatory rigor, and business leadership needed to guide high-growth companies in regulated industries.

Before joining Channel, Mr. Brown held senior financial roles across medtech and life sciences firms, where he built scalable financial infrastructure, led fundraising and M&A efforts, and aligned financial operations with commercialization goals.

“We’re thrilled to bring Robert on board,” said Nelson Whistance, President and Chief Executive Officer of Channel Medsystems. “His credentials and track record in financial leadership will be invaluable as we scale our operations and expand access to the Cerene® Cryotherapy Device.”

“I am honored to join Channel Medsystems at such a transformative moment,” said Robert Brown, MBA, CPA. “I believe deeply in Channel Medsystems’ mission to transform women’s healthcare. I look forward to supporting growth, strengthening financial operations, and helping advance broader access to safe and effective therapies.”

With Mr. Brown’s appointment, Channel Medsystems strengthens its executive team’s financial leadership to support sustained growth and strategic execution.

About Channel Medsystems
Channel Medsystems is a privately held company dedicated to transforming women’s healthcare globally through the development and commercialization of its flagship product, the Cerene® Cryotherapy Device. Cerene is a non-hormonal, incision-free treatment designed to provide safe, effective, and convenient therapy for women suffering from heavy menstrual bleeding (HMB) and dysmenorrhea. Offering a modern alternative to invasive surgery or long-term medications, Channel Medsystems is committed to improving patient outcomes, broadening access, and empowering women with greater control over their care.

For more information, visit cerene.com and follow us on LinkedIn.

Media Contact:
Tara Murphy
Vice President, Marketing
Channel Medsystems
tmurphy@cerene.com                                                                                                 
215-620-3004

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/65a78797-c385-4a5c-913b-5b17216e8d81

Channel Medsystems Appoints Robert Brown, MBA, CPA, as Chief Financial Officer




Channel Medsystems Appoints Robert Brown, MBA, CPA, as Chief Financial Officer

BERKELEY, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) — Channel Medsystems, Inc., a privately held company dedicated to advancing women’s health with innovative solutions, announced today the appointment of Robert Brown, MBA, CPA, as Chief Financial Officer.

Mr. Brown is a seasoned financial executive with deep expertise in strategic finance, operations, and growth planning for healthcare and medtech organizations. As an MBA and CPA, he brings the combination of strong financial acumen, regulatory rigor, and business leadership needed to guide high-growth companies in regulated industries.

Before joining Channel, Mr. Brown held senior financial roles across medtech and life sciences firms, where he built scalable financial infrastructure, led fundraising and M&A efforts, and aligned financial operations with commercialization goals.

“We’re thrilled to bring Robert on board,” said Nelson Whistance, President and Chief Executive Officer of Channel Medsystems. “His credentials and track record in financial leadership will be invaluable as we scale our operations and expand access to the Cerene® Cryotherapy Device.”

“I am honored to join Channel Medsystems at such a transformative moment,” said Robert Brown, MBA, CPA. “I believe deeply in Channel Medsystems’ mission to transform women’s healthcare. I look forward to supporting growth, strengthening financial operations, and helping advance broader access to safe and effective therapies.”

With Mr. Brown’s appointment, Channel Medsystems strengthens its executive team’s financial leadership to support sustained growth and strategic execution.

About Channel Medsystems
Channel Medsystems is a privately held company dedicated to transforming women’s healthcare globally through the development and commercialization of its flagship product, the Cerene® Cryotherapy Device. Cerene is a non-hormonal, incision-free treatment designed to provide safe, effective, and convenient therapy for women suffering from heavy menstrual bleeding (HMB) and dysmenorrhea. Offering a modern alternative to invasive surgery or long-term medications, Channel Medsystems is committed to improving patient outcomes, broadening access, and empowering women with greater control over their care.

For more information, visit cerene.com and follow us on LinkedIn.

Media Contact:
Tara Murphy
Vice President, Marketing
Channel Medsystems
tmurphy@cerene.com                                                                                                 
215-620-3004

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/65a78797-c385-4a5c-913b-5b17216e8d81

Life Backup Plan Rolls Out New Version During Medicare Open Enrollment Season and Employer Benefits Review




Life Backup Plan Rolls Out New Version During Medicare Open Enrollment Season and Employer Benefits Review

New release introduces unparalleled digital medical history and clinical intake capabilities, supporting hospitals, employers, individuals, families, and health insurers—and opens limited Showcase Partner slots for a forthcoming national TV appearance.

Aliso Viejo, CA, Nov. 20, 2025 (GLOBE NEWSWIRE) — Galacxia Inc., creator of the Life Backup Plan Interoperable Lifecare Platform, today announces a new version featuring a first-of-its-kind, comprehensive, standardized digital health patient workflow. The enhancement helps clinicians, hospitals, employers, individuals, families, caregivers, and health insurers collect robust medical and lifestyle information quickly. This improves safety, reduces delays, and strengthens decision-making across the entire care continuum.

Sandy Eulitt, founder and CEO of Galacxia Inc., works on the Life Backup Plan Interoperable Lifecare(TM) digital health platform.

The release coincides with Medicare Open Enrollment Season (October 15 through December 7) and the annual period when employers, hospitals, and health insurers finalize their benefit offerings for the coming year.

A comprehensive intake workflow that helps clinicians diagnose faster

Organizing the vital details clinicians most rely on: medications, surgical, family, and medical history, allergies, and symptoms, Life Backup Plan integrates with EHR systems, reducing healthcare workload and simplifying access to essential patient information.

“While recently recovering from cervical spine surgery, I used Life Backup Plan to check on me, medication tracking, and symptom monitoring.” reflected Sandy Eulitt, founder and CEO of Galacxia Inc. “Managing a post-operative infection, with numerous clinical visits, home health care, wound care, supply orders, medication changes, and nearly two emergency room visits, this new version extrapolates my personal experience into a clinically aligned system which gives providers the tools they need to deliver more connected care.”

Hospitals will benefit significantly from the enhancement. Through comprehensive post-discharge monitoring and reduced information gaps, Life Backup Plan helps organizations lower readmissions, strengthen JCAHO performance, improve care coordination, and reduce CMS penalties associated with preventable readmissions.

Clinician-approved approach to interoperability

“From a clinical operations standpoint, Life Backup Plan addresses a longstanding gap in healthcare: patient-driven interoperability,” said Dr. Allison Lamont, Chief Medical Officer of Life Backup Plan. “By aligning the platform with the standard intake information physicians rely upon, it improves the accuracy of clinical data, supports safer decision-making, and reduces inefficiencies across the system. It’s a practical, scalable solution that strengthens both care quality and continuity.”

Support for seniors, caregivers, and families—without limiting the platform’s reach

“In my work helping seniors choose Medicare coverage, I see how overwhelmed people of all ages feel—not because they lack ability, but because the healthcare system is so fragmented,” said Meredith Skurkey, a Medicare Advantage specialist. “Life Backup Plan is the first tool I’ve seen that brings medications, history, safety tools, and vital documents together in one secure, easy-to-use platform. It gives my clients clarity, confidence, and peace of mind—and helps them stay healthier and independent longer.”

Health insurance adjacent benefits

The platform reduces absenteeism and employee distraction by identifying and responding to illnesses and emergencies earlier. It also supports workers who care for aging parents or young children, resulting in improved productivity and fewer health and/or safety related disruptions.

Universal health and safety tool

Although the timing coincides with Open Enrollment, the platform remains universally beneficial for people of all ages. It supports anyone who may be by themselves at any time, including individuals living alone, outdoor enthusiasts, travelers, women, singles, and parents who want reassurance that their children arrived home safely. Whether someone is hanging Christmas lights, moving boxes, showering while home alone, or navigating safety risks that disproportionately affect women, the app provides a reliable safety net during falls, safety concerns, or medical emergencies.

Business Today Showcase Partner opportunity

Life Backup Plan will be featured in a “Maximizing the Healthcare Journey” segment on Business Today with Bill and Giuliana Rancic. The segment tapes in January, 2026, with the episode airing in March 2026. Galacxia Inc. is announcing a Showcase Partner Program for organizations that would like to be filmed on site and featured during the broadcast. Partners may also appear in short-form video reels, podcast content, social media, and related media packages. Interested organizations should contact Sandy Eulitt.

Official Business Today with Bill and Giuliana Rancic promotional artwork, provided for use in advance of the Life Backup Plan feature segment.

About Life Backup Plan by Galacxia, Inc

Life Backup Plan is a first-of-its-kind, interoperable digital health and safety platform built around the Five M’s of Health and Safety™: Monitoring, Medicine, Metrics, Money, and Membership. The platform provides early detection and rapid response for both illness and emergencies through intelligent check-ins, symptom tracking, medication logs, and passive alert escalation. These capabilities lower healthcare costs by identifying issues sooner, improving diagnostic speed, and enabling earlier intervention before complications develop. For emergent or non-emergent medical interaction, Life Backup Plan centralizes digital medical history, clinical intake data, allergies, family and surgical history, risk factors, and other essential health information in one secure, patient-managed system. This gives first responders, healthcare workers, and care teams immediate access to accurate, organized data that strengthens decision-making and improves care coordination across hospitals, outpatient care, home-based care, and recovery settings. Designed for people of all ages and lifestyles, Life Backup Plan supports individuals, families, aging in place, caregiving, disability support, post-discharge monitoring, women’s safety, dating and travel safety, outdoor recreation, and domestic violence and human trafficking prevention. The platform delivers health-insurance–adjacent benefits for employers by reducing absenteeism, minimizing avoidable health events, and supporting employees who care for aging parents or young children. Its comprehensive design helps hospitals, employers, insurers, and public agencies reduce preventable complications, lower costs, and improve safety, independence, and continuity of care for the people they serve.

Press inquiries

Life Backup Plan by Galacxia, Inc
https://www.lifebackupplan.com
Sandy Eulitt
founder@lifebackupplan.com
8588480860
49 El Prado Lane, Oceanside, CA 92058

A video accompanying this announcement is available at: https://www.youtube.com/embed/eNg74k-t2l4

Life Backup Plan Rolls Out New Version During Medicare Open Enrollment Season and Employer Benefits Review




Life Backup Plan Rolls Out New Version During Medicare Open Enrollment Season and Employer Benefits Review

New release introduces unparalleled digital medical history and clinical intake capabilities, supporting hospitals, employers, individuals, families, and health insurers—and opens limited Showcase Partner slots for a forthcoming national TV appearance.

Aliso Viejo, CA, Nov. 20, 2025 (GLOBE NEWSWIRE) — Galacxia Inc., creator of the Life Backup Plan Interoperable Lifecare Platform, today announces a new version featuring a first-of-its-kind, comprehensive, standardized digital health patient workflow. The enhancement helps clinicians, hospitals, employers, individuals, families, caregivers, and health insurers collect robust medical and lifestyle information quickly. This improves safety, reduces delays, and strengthens decision-making across the entire care continuum.

Sandy Eulitt, founder and CEO of Galacxia Inc., works on the Life Backup Plan Interoperable Lifecare(TM) digital health platform.

The release coincides with Medicare Open Enrollment Season (October 15 through December 7) and the annual period when employers, hospitals, and health insurers finalize their benefit offerings for the coming year.

A comprehensive intake workflow that helps clinicians diagnose faster

Organizing the vital details clinicians most rely on: medications, surgical, family, and medical history, allergies, and symptoms, Life Backup Plan integrates with EHR systems, reducing healthcare workload and simplifying access to essential patient information.

“While recently recovering from cervical spine surgery, I used Life Backup Plan to check on me, medication tracking, and symptom monitoring.” reflected Sandy Eulitt, founder and CEO of Galacxia Inc. “Managing a post-operative infection, with numerous clinical visits, home health care, wound care, supply orders, medication changes, and nearly two emergency room visits, this new version extrapolates my personal experience into a clinically aligned system which gives providers the tools they need to deliver more connected care.”

Hospitals will benefit significantly from the enhancement. Through comprehensive post-discharge monitoring and reduced information gaps, Life Backup Plan helps organizations lower readmissions, strengthen JCAHO performance, improve care coordination, and reduce CMS penalties associated with preventable readmissions.

Clinician-approved approach to interoperability

“From a clinical operations standpoint, Life Backup Plan addresses a longstanding gap in healthcare: patient-driven interoperability,” said Dr. Allison Lamont, Chief Medical Officer of Life Backup Plan. “By aligning the platform with the standard intake information physicians rely upon, it improves the accuracy of clinical data, supports safer decision-making, and reduces inefficiencies across the system. It’s a practical, scalable solution that strengthens both care quality and continuity.”

Support for seniors, caregivers, and families—without limiting the platform’s reach

“In my work helping seniors choose Medicare coverage, I see how overwhelmed people of all ages feel—not because they lack ability, but because the healthcare system is so fragmented,” said Meredith Skurkey, a Medicare Advantage specialist. “Life Backup Plan is the first tool I’ve seen that brings medications, history, safety tools, and vital documents together in one secure, easy-to-use platform. It gives my clients clarity, confidence, and peace of mind—and helps them stay healthier and independent longer.”

Health insurance adjacent benefits

The platform reduces absenteeism and employee distraction by identifying and responding to illnesses and emergencies earlier. It also supports workers who care for aging parents or young children, resulting in improved productivity and fewer health and/or safety related disruptions.

Universal health and safety tool

Although the timing coincides with Open Enrollment, the platform remains universally beneficial for people of all ages. It supports anyone who may be by themselves at any time, including individuals living alone, outdoor enthusiasts, travelers, women, singles, and parents who want reassurance that their children arrived home safely. Whether someone is hanging Christmas lights, moving boxes, showering while home alone, or navigating safety risks that disproportionately affect women, the app provides a reliable safety net during falls, safety concerns, or medical emergencies.

Business Today Showcase Partner opportunity

Life Backup Plan will be featured in a “Maximizing the Healthcare Journey” segment on Business Today with Bill and Giuliana Rancic. The segment tapes in January, 2026, with the episode airing in March 2026. Galacxia Inc. is announcing a Showcase Partner Program for organizations that would like to be filmed on site and featured during the broadcast. Partners may also appear in short-form video reels, podcast content, social media, and related media packages. Interested organizations should contact Sandy Eulitt.

Official Business Today with Bill and Giuliana Rancic promotional artwork, provided for use in advance of the Life Backup Plan feature segment.

About Life Backup Plan by Galacxia, Inc

Life Backup Plan is a first-of-its-kind, interoperable digital health and safety platform built around the Five M’s of Health and Safety™: Monitoring, Medicine, Metrics, Money, and Membership. The platform provides early detection and rapid response for both illness and emergencies through intelligent check-ins, symptom tracking, medication logs, and passive alert escalation. These capabilities lower healthcare costs by identifying issues sooner, improving diagnostic speed, and enabling earlier intervention before complications develop. For emergent or non-emergent medical interaction, Life Backup Plan centralizes digital medical history, clinical intake data, allergies, family and surgical history, risk factors, and other essential health information in one secure, patient-managed system. This gives first responders, healthcare workers, and care teams immediate access to accurate, organized data that strengthens decision-making and improves care coordination across hospitals, outpatient care, home-based care, and recovery settings. Designed for people of all ages and lifestyles, Life Backup Plan supports individuals, families, aging in place, caregiving, disability support, post-discharge monitoring, women’s safety, dating and travel safety, outdoor recreation, and domestic violence and human trafficking prevention. The platform delivers health-insurance–adjacent benefits for employers by reducing absenteeism, minimizing avoidable health events, and supporting employees who care for aging parents or young children. Its comprehensive design helps hospitals, employers, insurers, and public agencies reduce preventable complications, lower costs, and improve safety, independence, and continuity of care for the people they serve.

Press inquiries

Life Backup Plan by Galacxia, Inc
https://www.lifebackupplan.com
Sandy Eulitt
founder@lifebackupplan.com
8588480860
49 El Prado Lane, Oceanside, CA 92058

A video accompanying this announcement is available at: https://www.youtube.com/embed/eNg74k-t2l4

23andMe Research Institute Helps Reconnect African Diaspora to Their Roots with Release of 250+ High-Resolution African Genetic Groups




23andMe Research Institute Helps Reconnect African Diaspora to Their Roots with Release of 250+ High-Resolution African Genetic Groups

Major Scientific Expansion Provides the Most Detailed Look at African Ancestry on the Market, Helping to Bypass Historical ‘Brick Walls’ for Individuals with African Heritage

PALO ALTO, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) — For millions of Americans in the African diaspora, genealogical ties and records were severed by the transatlantic slave trade, creating a ‘brick wall’ for those seeking to know their full heritage. Today, 23andMe Research Institute announced a landmark expansion of its genetic ancestry reports and features, unveiling more than 250 high-resolution Genetic Groups across Africa. This significant update provides members with African heritage the most detailed and scientifically rigorous look at their roots currently available on the market, further establishing 23andMe Research Institute as the leader in detailed genetic ancestry.

“This is more than a scientific update; it’s a new chapter in the right to know your own story,” said Steven Micheletti, Ph.D, senior scientist of population genetics at 23andMe Research Institute. “For too long, individuals of African descent have hit a ‘brick wall’ in traditional genealogy, their paper trails erased by time and history. This update uses our advancements in the field of genetics to help bypass that wall. Seeing your West African ancestry trace to one of 57 specific groups in Nigeria, for example, can be a profound experience. We are incredibly proud to apply our science to help facilitate these powerful discoveries that restore human connection and a piece of lost heritage.”

The update represents an improvement by a factor of 10, moving from 25 African Genetic Groups to more than 250 — significantly improving the accuracy and specificity of ancestry results for the continent. More than 80% of 23andMe’s Black and African American customers on the latest V5 genotyping chip will now see matches to one or more of these high-resolution genetic groups, offering a new, more specific starting point for their ancestral journey.

Prior to this expansion, the organization’s ancestry reports and features already held one of the highest ratings from the International Society of Genetic Genealogy for “overall accuracy and sophistication of the biogeographical ancestry analysis.”

Powered by Community-Driven Science

This landmark update was made possible by the willing participation of thousands of research-consented 23andMe Research Institute members with documented ancestry in Africa. Their participation enabled the development of a more inclusive and detailed map of human history for everyone.

The expanded groups, which span Eastern, Middle, Southern, and Western Sub-Saharan Africa, include:

• 57 Nigerian genetic groups
• 44 Angolan & Congolese genetic groups
• 40 Ethiopian & Eritrean genetic groups
• 32 Ghanaian, Liberian & Sierra Leonean genetic groups
• And a total of 28 Somali, 22 Senegambian & Guinean, and 9 Sudanese genetic groups, among others.

While the vast majority of Black and African American 23andMe Research Institute members on the latest genotyping chip will receive one or more of these new groups, there is more work to do. The organization is committed to expanding its reference panels and refining its industry-leading science to bring this level of detail to all members.

23andMe Research Institute Continues to Innovate Genetic Ancestry

The expansion of African Genetic Groups follows closely on the heels of the organization’s major update to Ancestry Composition.

The Ancestry Composition update provided:

• Unmatched granularity in ancestry percentages with 33 new populations in Europe and 6 new populations in the Americas. With these two updates, there are now a total of more than 4,500 populations for members to explore.
• The platform’s algorithm was updated to eliminate “Broadly” and “Unassigned” categories in the default results view.
• A new state-of-the-art DNA phasing pipeline reduces errors and gives a more accurate estimate of genetic ancestry percentages, even if ancestry isn’t from Europe or the Americas.

The Ancestry Composition update (Version Seven) was particularly focused on improving two major metrics: precision and recall. Precision confirms how often a piece of DNA is correctly predicted from a specific population. Recall confirms how much DNA from a specific population is correctly identified. Working to maximize both precision and recall is critical to making Ancestry Composition and other ancestry features as accurate as possible.

The update improved the underlying science behind member reports and features including, Ancestry Composition, Ancestry Timeline, Parental Inheritance, and DNA Painting, among others, ensuring 23andMe Research Institute continues to deliver the most precise and reliable ancestry results in the industry.

About 23andMe Research Institute

23andMe Research Institute is a nonprofit medical research organization that enables people everywhere to access their genetic information, learn about themselves and participate in the world’s largest crowdsourced research initiative. The Institute aims to be the world’s most significant contributor to scientific advancement, uniting people with the common goal of improving health and deepening our understanding of DNA — the code of life.

Media Contact:
press@23andMe.com
Catherine Afarian
23andMe Research Institute
408.656.8872
catherine.afarian@23andme.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d399aa86-54bf-4897-85d9-85334b40b37c

Hydreight Technologies Ranked #77 Fastest-Growing Company in North America on the 2025 Deloitte Technology Fast 500™




Hydreight Technologies Ranked #77 Fastest-Growing Company in North America on the 2025 Deloitte Technology Fast 500™

VANCOUVER, British Columbia and LAS VEGAS, Nov. 20, 2025 (GLOBE NEWSWIRE) — Hydreight Technologies Inc. (“Hydreight” or the “Company”) (TSXV: NURS | OTCQB: HYDTF | FSE: SO6) today announced it ranked No. 77 on the 2025 Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America.

Hydreight’s Chief Executive Officer, Shane Madden, attributes the Company’s growth to the continued expansion of its compliant national telehealth and pharmacy infrastructure, and the rapid onboarding of partners to its VSDHOne direct-to-consumer (D2C) platform, which enables healthcare and wellness brands to launch nationwide in days instead of months. Madden said:

“Our revenue growth reflects one thing — the demand for a compliant, scalable, technology-driven healthcare infrastructure in the United States. We’re proud to see Hydreight recognized among the fastest-growing companies in North America. This ranking validates the work our team has done building a nationwide medical, pharmacy, and telehealth network that lets partners scale safely, responsibly, and profitably.”

“This year’s rankings highlight both enduring leadership and breakthrough momentum,” said Wolfe Tone, US Deloitte Private & Emerging Client Portfolio leader and partner, Deloitte Tax LLP. “More than half of the winners are prior honorees, yet the majority of the top ten are first-time entrants — demonstrating the staying power of established leaders alongside the accelerating growth of new innovators across key sectors. As in previous years, private companies continue to dominate, underscoring the agility that private enterprises bring to competitive markets, enabling the exceptional triple and quadruple digit growth reflected in these rankings.”

Hydreight previously ranked #56 on the 2024 Deloitte Technology Fast 500™ and #9 on Deloitte’s 2024 Technology Fast 50™ (Canada), and was recognized again in 2025 as one of Canada’s Technology Fast 50™ award winners.

Overall, 2025 Technology Fast 500 companies achieved revenue growth ranging from 122% to 29,738% over the three-year period, with an average growth rate of 1,079%.

About the 2025 Deloitte Technology Fast 500™

Now in its 31st year, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies — both public and private — in North America. Technology Fast 500 award winners are selected based on percentage fiscal-year revenue growth from 2021 to 2024.

To be eligible, companies must own proprietary intellectual property or technology that contributes significantly to operating revenue; have base-year revenues of at least US$50,000 and current-year revenues of at least US$5 million; have been in business for a minimum of four years; and be headquartered in North America.

On behalf of the Board of Directors

Shane Madden
Director and Chief Executive Officer
Hydreight Technologies Inc.

Contact
Email: ir@hydreight.com; Telephone: (702) 970-8112

Hydreight Technologies Inc Ranked Number 25 Technology Fast 50 winners 2025 | Deloitte Canada

Hydreight Technologies Inc Ranked Number 77 Fastest-Growing Company in North America on the 2025 Deloitte Technology Fast 500™

Hydreight Technologies Recognized as a Top 50 TSX Venture Exchange Company

About Hydreight Technologies Inc.

Hydreight Technologies Inc is building one of the largest mobile clinic networks in the United States. Its proprietary, fully integrated platform has hosted a network of over 3000 nurses, over 200 doctors and a pharmacy network through its Doctor networks across 50 states. The platform includes a built-in, easy-to-use suite of fully integrated tools for accounting, documentation, sales, inventory, booking, and managing patient data, which enables licensed healthcare professionals to provide services directly to patients at home, office or hotel. Hydreight is bridging the gap between provider compliance and patient convenience, empowering nurses, med spa technicians, and other licensed healthcare professionals. The Hydreight platform allows healthcare professionals to deliver services independently, on their own terms, or to add mobile services to existing location-based operations. Hydreight has a 503B pharmacy network servicing all 50 states and is closely affiliated with a U.S. certified e-script and telemedicine provider network.

About VSDHOne – Direct to Consumer Platform

Developed in partnership with Victory Square Technologies (CSE: VST) (OTC: VSQTF) (FWB: 6F6), Hydreight Technologies launched the VSDHOne (Read as VSDH-One) platform. VSDHOne simplifies the entry challenges for companies and medi-spa businesses to enter the online healthcare space compliantly. This platform will help all businesses to launch a direct-to-consumer healthcare brand in a matter of days in all 50 states. Compliant offerings include: GLP-1s, peptides, personalized healthcare treatments, sermorelin, testosterone replacement therapy (“TRT”), hair loss, skincare, sexual health and more. Hydreight invested in technology, legal and infrastructure to launch this platform. The VSDHOne platform offers a complete, and modular end-to-end solution for businesses looking to launch direct-to-consumer healthcare brands. From compliance and telemedicine technology to nationwide doctor and pharmacy networks, VSDHOne provides all the tools needed for a seamless entry into the online healthcare space. The platform is designed to significantly reduce the time and costs associated with launching such services, making it possible for businesses to go live in days instead of months.

Neither TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. This press release does not constitute an offer of securities for sale in the United States. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States absent U.S. registration or an applicable exemption from U.S. registration requirements.

Cautionary Note Regarding Forward-Looking Information

This press release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities and operating performance.

Investors are cautioned that forward-looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the ability to obtain requisite regulatory and other approvals with respect to the business operated by the Company and/or the potential impact of the listing of the Company’s shares on the TSXV on relationships, including with regulatory bodies, employees, suppliers, customers and competitors; changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; compliance with extensive government regulation; and the diversion of management time as a result of being a publicly listed entity. This forward-looking information may be affected by risks and uncertainties in the business of the Company and market conditions.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.